Product categories
Application notes (PDF format)

  Home


News and Press Releases

FLUOROUS TECHNOLOGIES RECEIVES SUBSTANTIAL SBIR GRANTS





Pittsburgh, June 30, 2004
Download this FTI news release (PDF).

Pittsburgh-based chemical technology firm Fluorous Technologies, Inc. (FTI) today announced that it has received two major research grants from the National Institutes of Health - General Medical Sciences (NIH-GMS). These funds will support the continued development and commercialization of fluorous chemistry. A Phase I Small Business Innovation Research (SBIR) project entitled Chiral Separations using Fluorous Triphasic Chemistry involves phase-partitioned liquid systems for purification of pharmaceutical chemicals. This new technology, invented and patented by FTI’s founder, is expected to be scalable to every stage of drug development and production.

FTI also received a Phase II SBIR grant entitled Rapid Fluorous Synthesis of Drug-like Small Molecules. The project’s objective is to expand FTI’s broad-based technology platform with new fluorous chemicals and techniques for the modern drug discovery environment, with emphasis on practical solutions that speed up the synthesis and separation process. The centerpiece of this important grant will be the development of a rapid fluorous synthesis toolkit for drug discovery chemists.

"Beyond the generous financial support of NIH, these awards are important validation of the scientific and commercial value of fluorous chemistry," said Dr. Philip E. Yeske, FTI’s President and CEO. "They also illustrate the remarkable scope of chemistry applications that can be enhanced with fluorous technology."

---

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products for the life science market. The company uses its patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. Fluorous chemistry enhances a wide range of applications, including medicinal chemistry, combinatorial chemistry, catalysis, peptide and oligonucleotide production, and proteomics. For more information please visit www.fluorous.com

For further information, please contact:

Fluorous Technologies

412-826-3050
or toll-free 877-FLUOROFLASH